S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition

Molecular Pharmacology

Volumn 53, Issue 2, 1998, Pages 213-220

  Le Mée, Sandrine ^a   Pierré, Alain ^b   Markovits, Judith ^a   Atassi, Ghanem ^b   Jacquemin Sablon, Alain ^a   Saucier, Jean Marie ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [9 HYDROXY 5,6 DIMETHYL 1 [N (DIMETHYLAMINO)ETHYL]CARBAMOYL] 6H PYRIDO[4,3 B]CARBAZOLE; 2 [9 HYDROXY 5,6 DIMETHYL 1 [N 2 (DIMETHYLAMINO)ETHYL]CARBAMOYL] 6H PYRIDO[4,3 B]CARBAZOLE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); OLIVACINE; OLIVACINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA BINDING; DNA CLEAVAGE; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031934818     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.53.2.213     Document Type: Article

References (32)

1. Auclair C, Pierré A, Voisin E, Pepin O, Cros S, Colas C, Saucier J-M, Verschuere B, Gros P, and Paoletti C (1987) Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxy ellipticinium-chloride, HC1. Cancer Res 47:6254-6261.
2. Berger JM, Gamblin SJ, Harrison SC, and Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature (Lond) 379:225-232.
3. Chaires JB (1996) Dissecting the free energy of drug binding to DNA. Anti-Cancer Drug Design 11:569-580.
4. Chaires JB, Dattagupta N, and Crothers DM (1982) Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. Biochemistry 21:3933-3940.
5. Charcosset J-Y, Salles B, and Jacquemin-Sablon A (1983) Uptake and cytofluorescence localization of ellipticine derivatives in sensitive and resistant Chinese hamster lung cells. Biochem Pharm 32:1037-1043.
6. Chen AY and Liu LF (1994) DNA topoisnmerases, essential enzymes and lethal targets. Anna Rev Pharmacol Toxicol 34:191-218.
7. Depew DE and Wang JC (1975) Conformational fluctuations of DNA helix Proc Natl Acad Sci USA 72:4275-4279.
8. Dereuddre S, Delaporte C, and Jacquemin-Sablon A. (1997) Role of topoisomerase IIβ in the resistance of 9-OH-ellipticine resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res 57:4301-4308.
9. Fossé P, René B, Charra M, Paoletti C, and Saucier J-M (1992) Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship. Mol Pharmacol 42:590-595.
10. Fossé P, René B, Le Bret M, Paoletti C, and Saucier J-M (1991) Sequence requirements for mammalian topoisomerase II-mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res 19:2861-2868.
11. Froelich-Ammon SJ, Patchan MW, Osheroff N, and Thompson RB (1995). Topoisomerase II binds to ellipticine in the absence or presence of DNA. J Biol Chem 270:14998-15004.
12. Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon M-H, Burbridge M, Pierré A, and Atassi G (1997) Antitumor activity of S16020-2 in two orthotopic models of lung cancer. Anti-Cancer Drugs 8:276-282.
13. Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon M-H, Jan M, Burbridge M, Visalli M, Bisagni E, Pierré A, and Atassi G (1996) In vivo antitumor activity of S16020-2, a new olivacine derivative. Cancer Chemother Pharmacol 38:513-521.
14. Jasztold-Howorko R, Landras C, Pierré A, Atassi G, Guilbaud N, Kraus-Berthier L, Léonce S, Rolland Y, Prost J-F, and Bisagni E (1994) Synthesis and evaluation of 9-hydroxy-5-methyl-(and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazole-1-N-[(dialkylamino)alkyl]carboxamides, a new promising series of antitumor olivacine derivatives. J Med Chem 37:2445-2452.
15. Khélifa T, Casabianca-Pignède M-R, René B, and Jacquemin-Sablon A (1994) Expression of topoisomerases II α and in Chinese hamster lung cells resistant to topoisomerase II inhibitors. Mol Pharmacol 46:323-328.
16. Kohn KW, Ewig RAG, Erickson LC, and Zwelling LA (1981) Measurement of DNA strand breaks and cross-links by alcaline elution, in DNA Repair: A Laboratory Manual of Research Procedures (Friedberg EC and Hanawalt PC, eds) pp 379-401, Marcel Dekker, New York.
17. Koo H-M, Monks A, Mikheev A, Rubinstein LV, Gray-Goodrich M, McWilliams MJ, Alvord W, Oie HK, Gazdar AF, Paull KD, Zarbl H, and Vande Woude GF (1996) Enhanced sensitivity to 1-β-D-arabinoniranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res 56: 5211-5216.
18. Kraus-Berthier L, Guilbaud N, Jan M, Saint-Dizier D, Rouillon MH, Burbridge MF, Pierré A, and Atassi G (1997) Experimental antitumor activity of S16020-2 in a panel of human tumors. Eur J Cancer 33:1881-1887.
19. Lambert B, Jones BK, Roques BP, Le Pecq J-B, and Yeung AT (1989) The noncovalent complex between DNA and the bifunctional intercalator ditercalinium is a substrate for the UvrABC endonuclease of Escherichia coli. Proc Natl Acad Sci USA 86:6557-6561.
20. Léonce S, Pérez V, Casabianca-Pignède M-R, Anstett M, Bisagni E, Pierré A, and Atassi G (1996) In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest New Drugs 14:169-180.
21. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Anna Rev Biochem 58:351-375.
22. Liu LF and Miller KG (1981) Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerase from HeLa cell nuclei. Proc Natl Acad Sci USA 78:3487-3491.
23. McGhee JD and von Hippel PH (1974) Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J Mol Biol 86:469-489.
24. Pommier Y, Fesen M, and Goldwasser F (1996) Topoisomerase II inhibitors: the epipodophyllotoxins, m-AMSA, and the ellipticine derivatives, in Cancer Chemotherapy and Biotherapy, 2nd ed (Chabner BA and Longo DL, eds) pp 435-461, Lippincott-Raven, Philadelphia.
25. Pommier Y, Schwartz RE, Zwelling LA, Kerrigan D, Mattern MR, Charcosset J-Y, Jacquemin-Sablon A, and Kohn KW (1986) Reduced formation of protein-associated DNA strand-breaks in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46:611-616.
26. Robinson MJ and Osheroff N (1991) Effects of antineoplastic drugs on the poststrand passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 30:1807-1813.
27. Ross WE, Glaubiger DL, and Kohn KW (1979) Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim Biophys Acta 562:41-50.
28. Salles B, Charcosset J-Y, and Jacquemin-Sablon A (1982) Isolation and properties of Chinese hamster lung cells resistant to ellipticine derivatives. Cancer Treat Rep 66:327-337.
29. Sambrook J, Fritsch EF, and Maniatis T (1989) Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
30. Saucier J-M, Festy B, and Le Pecq J-B (1971) The change of the torsion of the DNA helix caused by intercalation. II: Measurement of the relative change of torsion induced by various intercalating drugs. Biochimie 53:973-980.
31. Sorensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB, and Westergaard O (1992) Mode of action of topoisomerase II-targeting agents at a specific DNA sequence: uncoupling the DNA binding, cleavage and religation events. J Mol Biol 228:778-786.
32. Worland ST and Wang JC (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisae. J Biol Chem 264:4412-4416.